Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-10-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523316300717 |
| _version_ | 1819180510687002624 |
|---|---|
| author | Domenico Ribatti Beatrice Nico Simona Ruggieri Roberto Tamma Giovanni Simone Anita Mangia |
| author_facet | Domenico Ribatti Beatrice Nico Simona Ruggieri Roberto Tamma Giovanni Simone Anita Mangia |
| author_sort | Domenico Ribatti |
| collection | DOAJ |
| description | Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. MVD in both basal-like and TNBC is significantly higher than in non–basal-like and non-TNBC. In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy. |
| first_indexed | 2024-12-22T22:15:29Z |
| format | Article |
| id | doaj.art-694f4fee82424e899098cfe9e0a9fc6f |
| institution | Directory Open Access Journal |
| issn | 1936-5233 1944-7124 |
| language | English |
| last_indexed | 2024-12-22T22:15:29Z |
| publishDate | 2016-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-694f4fee82424e899098cfe9e0a9fc6f2022-12-21T18:10:47ZengElsevierTranslational Oncology1936-52331944-71242016-10-019545345710.1016/j.tranon.2016.07.002Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancerDomenico Ribatti0Beatrice Nico1Simona Ruggieri2Roberto Tamma3Giovanni Simone4Anita Mangia5Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, ItalyPathology Department, IRCCS Istituto Tumori “Giovanni Paolo II,” Bari, ItalyFunctional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II,” Bari, ItalySeveral data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. MVD in both basal-like and TNBC is significantly higher than in non–basal-like and non-TNBC. In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy.http://www.sciencedirect.com/science/article/pii/S1936523316300717 |
| spellingShingle | Domenico Ribatti Beatrice Nico Simona Ruggieri Roberto Tamma Giovanni Simone Anita Mangia Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer Translational Oncology |
| title | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| title_full | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| title_fullStr | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| title_full_unstemmed | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| title_short | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| title_sort | angiogenesis and antiangiogenesis in triple negative breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1936523316300717 |
| work_keys_str_mv | AT domenicoribatti angiogenesisandantiangiogenesisintriplenegativebreastcancer AT beatricenico angiogenesisandantiangiogenesisintriplenegativebreastcancer AT simonaruggieri angiogenesisandantiangiogenesisintriplenegativebreastcancer AT robertotamma angiogenesisandantiangiogenesisintriplenegativebreastcancer AT giovannisimone angiogenesisandantiangiogenesisintriplenegativebreastcancer AT anitamangia angiogenesisandantiangiogenesisintriplenegativebreastcancer |